Medytox, led by Hyunho Jung, made a groundbreaking announcement on December 13th: its subsidiary, Newmeco, has unveiled 'NEWLUX,' the latest botulinum toxin product.

NEWLUX, authorized by the Ministry of Food and Drug Safety (MFDS) in August, revolutionizes toxin production by eliminating animal-derived elements, minimizing neurotoxic protein denaturation, and reducing post-procedural side effects from chemical exposure.

Moreover, by excluding animal-derived components, particularly human serum albumin, among 900 kDa botulinum toxin products, Newmeco addresses potential allergic reactions. This innovation aims to meet market expectations of heightened efficacy, stability, and allergen-related concerns.

The product's pre-launch interest has surged, with this month's entire production already pre-ordered. Newmeco, operating across Medytox's three factories, aims to swiftly dominate the South Korean toxin market and plans tailored international expansion strategies from the latter half of next year.

Ju Hee-seok, CEO of Newmeco, expressed, "Market interest in Newlux has been fervent, with all this month's production already pre-booked even before its launch." He emphasized the focus on production expansion to claim a top spot in the domestic toxin market, leveraging robust sales and marketing capabilities.

Newlux, a product of Medytox's subsidiary Newmeco, signifies the next-gen botulinum toxin. Its launch expands Medytox's toxin portfolio to four products, strengthening its market presence alongside 'Meditoxin,' 'Coretox,' and 'Innotox.'